SymBio Pharmaceuticals Limited

TSE:4582 Lagerbericht

Marktkapitalisierung: JP¥10.7b

SymBio Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for SymBio Pharmaceuticals.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum11.9%
Wachstumsrate der Einnahmenn/a
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

None

Zuletzt aktualisiertn/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Aug 06
SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Jun 11
Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09
Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18
If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da SymBio Pharmaceuticals jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

TSE:4582 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
9/30/20243,066-4,019N/AN/AN/A
6/30/20243,695-3,424-1,349-1,105N/A
3/31/20244,642-2,743N/AN/AN/A
12/31/20235,589-1,962-426-194N/A
9/30/20237,074-1,164N/AN/AN/A
6/30/20238,313-8181228N/A
3/31/20239,2371,020N/AN/AN/A
12/31/202210,0081,1791,5671,614N/A
9/30/202210,0593,262N/AN/AN/A
6/30/20229,9833,3462,7002,763N/A
3/31/20229,1522,405N/AN/AN/A
12/31/20218,2572,03276140N/A
9/30/20216,208-1,071N/AN/AN/A
6/30/20214,773-2,411-4,067-3,990N/A
3/31/20213,856-3,308N/AN/AN/A
12/31/20202,987-4,090-4,271-4,122N/A
9/30/20203,162-3,430N/AN/AN/A
6/30/20202,193-4,191-5,026-4,847N/A
3/31/20201,778-4,751N/AN/AN/A
12/31/20192,838-4,376-4,567-4,351N/A
9/30/20192,811-4,452N/AN/AN/A
6/30/20193,912-3,434-2,148-2,024N/A
3/31/20194,559-2,610N/AN/AN/A
12/31/20183,836-2,753-2,364-2,325N/A
9/30/20184,060-2,373N/AN/AN/A
6/30/20183,587-4,100N/A-4,368N/A
3/31/20183,463-4,155N/AN/AN/A
12/31/20173,444-3,978N/A-3,817N/A
9/30/20173,377-3,943N/AN/AN/A
6/30/20172,943-2,404N/A-2,093N/A
3/31/20173,045-2,243N/AN/AN/A
12/31/20162,368-2,313N/A-1,960N/A
9/30/20162,008-3,488N/AN/AN/A
6/30/20162,168-3,131N/A-2,488N/A
3/31/20161,718-2,864N/AN/AN/A
12/31/20151,933-2,632N/A-2,272N/A
9/30/20151,939-1,232N/AN/AN/A
6/30/20151,956-1,077N/A-951N/A
3/31/20152,190-1,082N/AN/AN/A
12/31/20141,955-1,116N/A-1,266N/A
9/30/20141,557-1,358N/AN/AN/A
6/30/20141,697-1,506N/A-1,542N/A
3/31/20141,217-1,707N/AN/AN/A
12/31/20131,532-1,605N/A-1,677N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 4582's forecast earnings growth is above the savings rate (0.3%).

Ertrag vs. Markt: Insufficient data to determine if 4582's earnings are forecast to grow faster than the JP market

Hohe Wachstumserträge: Insufficient data to determine if 4582's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if 4582's revenue is forecast to grow faster than the JP market.

Hohe Wachstumseinnahmen: Insufficient data to determine if 4582's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 4582's Return on Equity is forecast to be high in 3 years time

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y